This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, L. P. Articles by Schilder, R. J. Search for Related Content PubMed PubMed Citation Articles by Martin, L. P. Articles by Schilder, R. J.

Platinum Resistance: The Role of DNA Repair Pathways

Authors' Affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Requests for reprints: Lainie P. Martin, Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. E-mail: Lainie.Martin{at}fccc.edu.

Abstract

Although platinum chemotherapeutic agents such as carboplatin, cisplatin, and oxaliplatin are used to treat a broad range of malignant diseases, their efficacy in most cancers is limited by the development of resistance. There are multiple factors that contribute to platinum resistance but alterations of DNA repair processes have been known for some time to be important in mediating resistance. Recently acquired knowledge has provided insight into the molecular mechanisms of DNA repair pathways and their effect on response to chemotherapy. This review will discuss the most important DNA repair pathways known to be involved in the platinum response, i.e., nucleotide excision repair (NER) and mismatch repair (MMR), and will briefly touch on the role of BRCA in DNA repair. The therapeutic implications of alterations in DNA repair which affect response to platinum in the treatment of patients with malignant disease, such as excision repair cross-complementation group 1 (ERCC1) deficiency and mismatch repair deficiency, will be reviewed.

This article has been cited by other articles:

				J.-P. Guo, S.-K. Shu, L. He, Y.-C. Lee, P. A. Kruk, S. Grenman, S. V. Nicosia, G. Mor, M. J. Schell, D. Coppola, et al. Deregulation of IKBKE Is Associated with Tumor Progression, Poor Prognosis, and Cisplatin Resistance in Ovarian Cancer Am. J. Pathol., July 1, 2009; 175(1): 324 - 333. [Abstract] [Full Text] [PDF]

				T. Hay, J. R. Matthews, L. Pietzka, A. Lau, A. Cranston, A. O.H. Nygren, A. Douglas-Jones, G. C.M. Smith, N. M.B. Martin, M. O'Connor, et al. Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin Cancer Res., May 1, 2009; 69(9): 3850 - 3855. [Abstract] [Full Text] [PDF]

				J. Dejmek, J. D. Iglehart, and J.-B. Lazaro DNA-Dependent Protein Kinase (DNA-PK)-Dependent Cisplatin-Induced Loss of Nucleolar Facilitator of Chromatin Transcription (FACT) and Regulation of Cisplatin Sensitivity by DNA-PK and FACT Mol. Cancer Res., April 1, 2009; 7(4): 581 - 591. [Abstract] [Full Text] [PDF]